{
    "version": "v1.0",
    "description": "55 questions generated by Gemini 2.5 Pro (https://g.co/gemini/share/e9784eda9652) using 10 documents from our dataset with 5 questions generated per document and the last 5 questions require information from multiple documents.",
    "questions": [
        {
            "id": 51,
            "question": "Compare the study populations and primary risk metrics used to assess the risk of second cancers in survivors of adolescent and young adult (AYA) cancer in the TYACSS study versus the KPSC cohort study.",
            "answer": "The Teenage and Young Adult Cancer Survivor Study (TYACSS) was a large, population-based cohort of 200,945 survivors diagnosed at ages 15-39 in England and Wales between 1971 and 2006. It primarily focused on the Absolute Excess Risk (AER), which measures the number of subsequent neoplasms beyond what is expected in the general population. The Kaiser Permanente Southern California (KPSC) study was a retrospective matched cohort study of 10,574 survivors diagnosed at ages 15-39 between 1990 and 2012. It compared survivors to an internal, matched comparison cohort without a history of cancer and used the Incidence Rate Ratio (IRR) as its primary risk metric, finding a 2.6-fold greater risk of developing a second cancer.",
            "reference": [
                "PMC6494975.plain.txt",
                "PMC6563559.plain.txt"
            ]
        },
        {
            "id": 52,
            "question": "Two St Jude Lifetime Cohort studies investigated the role of germline mutations on subsequent neoplasm (SN) risk in childhood cancer survivors. How did the focus of these two studies differ in terms of the types of genes analyzed?",
            "answer": "One study focused specifically on pathogenic germline mutations (PGMs) in 127 genes from 6 major DNA repair pathways, investigating how these mutations, in combination with cancer treatment exposures, affect SN risk. The other study took a broader approach, assessing P/LP mutations in 60 genes known to be associated with autosomal dominant cancer predisposition syndromes to determine their contribution to SN risk, and stratified the risk by radiation exposure.",
            "reference": [
                "PMC7430217.plain.txt",
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 53,
            "question": "Based on the provided studies, what is the role of the CALR mutation in myeloproliferative neoplasms (MPNs), and what advanced technique was used in one study to link this genotype to its specific transcriptional effects?",
            "answer": "The CALR mutation is a key driver mutation in myeloproliferative neoplasms (MPNs), alongside JAK2 and MPL, and is the sole abnormality in a significant portion of patients. To investigate its specific effects, one study developed and applied the 'Genotyping of Transcriptomes (GoT)' method. This technique integrates genotyping with single-cell RNA sequencing to directly link the CALR mutation to its transcriptional output in individual hematopoietic progenitor cells, revealing that the mutation increases cell fitness and proliferation, particularly with myeloid differentiation, and activates the unfolded protein response.",
            "reference": [
                "PMC7030948.plain.txt",
                "PMC6782071.plain.txt"
            ]
        },
        {
            "id": 54,
            "question": "Compare the findings regarding the risk of subsequent breast cancer in female survivors of Hodgkin lymphoma across the TYACSS, KPSC, and St. Jude cohort studies.",
            "answer": "The TYACSS study on AYA survivors found that female survivors of Hodgkin lymphoma had a very high absolute excess risk (AER) of 55.7 per 10,000 person-years for any subsequent neoplasm, with breast cancer being a major contributor. The KPSC study on AYA survivors found that lymphoma survivors had an elevated risk for developing a breast SMN, with an adjusted IRR of 2.31. The St. Jude study on childhood cancer survivors found that pathogenic/likely pathogenic mutations were associated with a significantly increased rate of subsequent breast cancer among irradiated survivors, with a relative rate of 13.9.",
            "reference": [
                "PMC6494975.plain.txt",
                "PMC6563559.plain.txt",
                "PMC6036620.plain.txt"
            ]
        },
        {
            "id": 55,
            "question": "How do the challenges of AI in cancer imaging relate to the findings on the impact of the COVID-19 pandemic on cancer-related encounters?",
            "answer": "The AI in cancer imaging review highlights AI's potential for early detection, characterization, and monitoring of tumors, tasks that can improve efficiency and accuracy. The study on the effects of the COVID-19 pandemic showed a drastic decline in cancer-related patient encounters, particularly a drop of over 80% in breast and colorectal cancer screenings. This suggests a future surge in patients presenting with later-stage cancer. AI-based detection tools could be critical in managing the resulting backlog of screening procedures and helping to rapidly identify suspicious findings from the large volume of returning patients, potentially mitigating some of the negative effects of delayed diagnosis.",
            "reference": [
                "PMC6403009.plain.txt",
                "PMC7444638.plain.txt"
            ]
        }
    ]
}